User profiles for Angela Huttner
Angela HuttnerGeneva University Hospital Verified email at hcuge.ch Cited by 5714 |
Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum
A Huttner, S Harbarth, J Carlet, S Cosgrove… - … resistance and infection …, 2013 - Springer
Antimicrobial resistance (AMR) is now a global threat. Its emergence rests on antimicrobial
overuse in humans and food-producing animals; globalization and suboptimal infection …
overuse in humans and food-producing animals; globalization and suboptimal infection …
Phase 1 trials of rVSV Ebola vaccine in Africa and Europe
ST Agnandji, A Huttner, ME Zinser… - … England Journal of …, 2016 - Mass Medical Soc
Background The replication-competent recombinant vesicular stomatitis virus (rVSV)–based
vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety …
vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety …
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial
A Huttner, JA Dayer, S Yerly, C Combescure… - The Lancet Infectious …, 2015 - thelancet.com
Background Safe and effective vaccines against Ebola could prevent or control outbreaks.
The safe use of replication-competent vaccines requires a careful dose-selection process. We …
The safe use of replication-competent vaccines requires a careful dose-selection process. We …
Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials
A Huttner, EM Verhaegh, S Harbarth… - Journal of …, 2015 - academic.oup.com
Objectives Nitrofurantoin's use has increased exponentially since recent guidelines
repositioned it as first-line therapy for uncomplicated lower urinary tract infection (UTI). We …
repositioned it as first-line therapy for uncomplicated lower urinary tract infection (UTI). We …
Effect of C-reactive protein–guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated …
Importance Antibiotic overuse drives antibiotic resistance. Gram-negative bacteremia is a
common infection that results in substantial antibiotic use. Objective To compare the clinical …
common infection that results in substantial antibiotic use. Objective To compare the clinical …
How to use biomarkers of infection or sepsis at the bedside: guide to clinicians
Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host
response to infection. In this context, biomarkers could be considered as indicators of either …
response to infection. In this context, biomarkers could be considered as indicators of either …
An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units
…, O Frey, S Harbarth, A Huttner… - Journal of …, 2014 - academic.oup.com
Objectives Emerging evidence supports the use of therapeutic drug monitoring (TDM) of β-lactams
for intensive care unit (ICU) patients to optimize drug exposure, although limited …
for intensive care unit (ICU) patients to optimize drug exposure, although limited …
Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study
A Huttner, E Von Dach, A Renzoni, BD Huttner… - International journal of …, 2015 - Elsevier
Whilst augmented renal clearance (ARC) is associated with reduced β-lactam plasma
concentrations, its impact on clinical outcomes is unclear. This single-centre prospective, …
concentrations, its impact on clinical outcomes is unclear. This single-centre prospective, …
[HTML][HTML] Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study
Objectives To evaluate longitudinally the persistence of humoral immunity for up to 6 months
in a cohort of hospital employees with mild coronavirus disease 2019 (COVID-19). Methods …
in a cohort of hospital employees with mild coronavirus disease 2019 (COVID-19). Methods …
Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary …
A Huttner, C Hatz, G van den Dobbelsteen… - The Lancet infectious …, 2017 - thelancet.com
Background Escherichia coli infections are increasing worldwide in community and hospital
settings. The E coli O-antigen is a promising vaccine target. We aimed to assess the safety …
settings. The E coli O-antigen is a promising vaccine target. We aimed to assess the safety …